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Abstract
Introduction: Surgical orbital decompression involves removal of one or more of the
orbital bony walls in order to gain space for overgrown muscles and adipose tissue,
which results in a reduction in pressure on the eye. This observational study aims to
perform  an  endocrinological  assessment  of  the  surgical  treatment  outcomes of
thyroid eye disease (TED) patients before and after orbital decompression. 
Material and methods: This retrospective study included 51 TED patients (84 orbits)
who  underwent  endoscopic  orbital  decompression  (EOD)  or  balanced  orbital
decompression. The effect of surgical treatment was evaluated via the clinical activity
score (CAS), and modified NOSPECS and EUGOGO classification.
Results:  Before orbital  decompression,  the average CAS index was 3.83 ± 1.86
points, whereas the modified NOSPECS score was 3.31 ± 0.97 points. After surgical
intervention, the values were as follows: 2.07 ± 1.84 points for CAS and 2.5 ± 0.97
points for  modified NOSPECS. The EUGOGO classification before surgery showed
that Graves’ orbitopathy (GO) was mild, moderate to severe, and sight-threatening in
1%, 25%, and 74% of the orbits, respectively. After surgery, GO was determined to
be mild, moderate to severe, and sight-threatening in 24%, 57%, and 19% of the
orbits, respectively.  Statistical analysis was performed using the R 3.6.2 statistical
environment. Inference about the statistical reliability of the parameter was made by
calculating the mean and the 95% credibility interval (CI). 
Conclusions: The severity of TED decreased after orbital decompression. The CAS,
and modified NOSPECS and EUGOGO classification showed a statistically reliable
postoperative  reduction.  The  drop  in  activity  of  the  disease  after  orbital  surgery
requires careful follow-up.
Key  words:  thyroid  eye  disease;  orbital  decompression;  CAS;  NOSPECS  classification;
EUGOGO classification
Introduction
Thyroid eye disease (TED) is defined as a chronic disease involving the soft tissues of the
orbit. The disease is autoimmune, mostly occurring in the course of Graves’ disease (90%)
and rarely in  Hashimoto’s  disease  (5%),  or  in  patients  without  any symptoms of  thyroid
disease (5%) [1]. Infiltrative-oedematous changes in the orbit are nowadays found in 10%–
30% of patients with Graves’ disease, of whom 1% of patients could turn blind due to optic
neuropathy, corneal ulceration, or globe subluxation [2–4]. The criteria for the diagnosis of
TED  include  the  presence  of  inflammation  of  the  orbital  soft  tissues,  proptosis  and
disturbances  in  the  mobility of  the  eye,  and visual  acuity disturbances  [1,  3,  5].  TED is
considered as a multi-phase disease. In its natural course, an active/inactive phase and plateau
can be distinguished. In the first phase, which lasts from several months to several years, the
inflammatory process dominates in the soft tissues of the orbit. Meanwhile, the inactive phase
is  the  phase  when  the  disease  stabilises  and  the  inflammation  is  suppressed.  However,
changes resulting from the fibrosis and scarring of the soft tissues of the orbit will most likely
become permanent. In the first year of the disease 65% of patients experience a spontaneous
2
regression of symptoms resulting from orbital soft tissues; 20% remain stable, whereas 15%
deteriorate  [2,  5–7].  Care  for  TED patients  is  multidisciplinary.  The  team caring  for  the
patient should include an endocrinologist,  ophthalmologist,  otorhinolaryngologist,  surgeon,
maxillofacial  surgeon,  radiotherapist,  and  nuclear  medicine  specialist  [1].  Due  to  the
insufficient knowledge about the aetiology of the disease, no causative treatment is available.
The  treatment  is  only  symptomatic  [2] and  includes  non-surgical  or  surgical  orbital
decompression  [6].  Non-surgical  methods of  orbital  decompression  include glucocorticoid
therapy (GCs) or other immunosuppressive pharmacotherapy and orbital radiotherapy (RTH)
[1,  3,  8].  Meanwhile,  orbital  decompression  is  required  when  no  improvement  after
conservative  treatment  is  observed.  Surgical  treatment  can  also  be  considered  as  a
rehabilitative eye surgery in the inactive phase of the disease [1].
Surgical orbital decompression involves removal of one or more orbital bony walls [3, 9–12].
The main  purpose  of  orbital  decompression  is  to  gain  space  for  overgrown muscles  and
adipose tissue to lower the intraocular pressure, which results in a reduction in pressure on the
eye  [13].  In  principle,  each of the four  orbital  bone walls  can be decompressed  [14–16].
Currently, the most commonly used type of orbital decompression is endoscopic medial wall
decompression and its expansion or inferomedial decompression performed together with the
decompression of  the lateral  wall  [17–21].  The main advantages  of endoscopic intranasal
orbital decompression are as follows: a relatively simple surgical technique, a good insight
into  the  operating  field,  the  ability  to  assess  the  content  of  the  orbit,  the  possibility  to
accurately  control  the  movement  of  fat  into  the  nasal  cavity,  easy  identification  of  the
oculomotor muscles, preservation of the physiological drainage path of the paranasal sinuses,
and short hospitalisation of the patient. The choice of technique and surgical access depends
on the surgeon’s experience  [19]. Thus, in this study, we aim to investigate the impact of
orbital decompression on patients with TED based on the CAS, and the modified NOSPECS
and EUGOGO classification. 
Material and methods
This study included a group of 51 patients (84 orbits) who were diagnosed with TED and
required  orbital  decompression.  Surgery  was  performed  in  the  Department  of
Otorhinolaryngology  of  the  Faculty  of  Medicine  and  Dentistry,  Medical  University  of
Warsaw. The study group consisted of adult patients of both genders (17 men, 34 women),
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aged 25 to 79 years (average 51.37 ± 13.24 years) and hospitalised in the department between
2012 and 2018. Consent from the Bioethics Committee was obtained (KB/69/2018).
The inclusion criteria are as follows: (1) a diagnosis of TED, (2) no orbital decompression in
the past,  (3)  available  pre-  and postoperative  ophthalmological  examinations,  (4)  over  18
years of age, and (5) available patient informed consent. Consent was obtained from each
patient after a full explanation of the purpose and nature of all procedures used. Meanwhile,
the exclusion criteria are as follows: (1) an indication other than TED for orbital surgery, (2)
follow-up period less than 3 months, (3) under 18 years of age, and (4) lack of informed
consent for the study.
In  all  patients,  the  data  on  preoperative  non-surgical  treatment  was  collected:  antithyroid
drugs, radioiodine treatment, strumectomy, orbital radiotherapy, GCs (IV), and TSH receptor
antibodies.
Endocrinological  assessment  based  on  the  clinical  activity  score  (CAS),  and  modified
NOSPECS and EUGOGO classification was performed:
— preoperatively:  in  the  period  ranging  from  1  week  to  3  months  before  orbital
decompression;
— postoperatively:  in  the  period  ranging  from  1  week  to  3  months  after  orbital
decompression
For the evaluation of orbital soft tissue symptoms in TED patients, the seven-point
CAS classification was used  — a tool that measures major clinical symptoms of Graves’
orbitopathy (GO) and defines activity of the disease (Supplementary Tab. 1). The range of
points in CAS is from 0 to 7. A score of 3 or more indicates active inflammation, while a
score of less than 3 indicates the inactive phase.
Modified NOSPECS classification (Supplementary Tab. 2) sums up the points obtained in
each class (N, O, S, P, E, C, S) r to determine the stage (severity) of the disease. Zero points
were given for symptoms in class N. For symptoms assigned to each of the other classes, 1
point was awarded, i.e.  a total  of 0 to 6 points.  The greater  the number of points in the
NOSPECS classification, the more advanced the disease stage. There are a few modifications
in the NOSPECS classification, in which the ophthalmic parameters used for its assessment
are changed, the number of assessed parameters is reduced, or the scoring method is different
[22–25].
TED severity according to the EUGOGO classification (Supplementary Tab. 3) distinguishes
three types of thyroid orbitopathy: mild, severe to moderate, or sight-threatening.
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In  the  case  of  multi-stage  surgical  treatment,  the  final  endocrinological  assessment  is
performed after the completion of the surgical treatment. In this study, we assess the effect of
the previously applied conservative treatment and the type of selected surgical technique on
the  results  of  TED  treatment  with  orbital  decompression,  according  to  the  selected
endocrinological classifications.
Statistical analysis
Statistical  analysis  was  performed  using  the  R  3.6.2  statistical  environment.  Hierarchical
regression analyses in Bayesian terms were performed using the brms package. Goodness of
fit was assessed using LOOIC statistics (leave-one-out information criterion). Inference about
the statistical reliability of the parameter was made by calculating the mean and the 95%
credibility interval (CI). Before and after surgical treatment of TED, each eye was assessed
using  three  different  endocrinological  classifications:  CAS,  GO severity  according  to  the
modified NOSPECS classification, and GO severity according to the EUGOGO classification.
To analyse the effects  of the operation (measurement)  and covariates,  hierarchical ordinal
regressions were performed. The selection of this group of analyses resulted from the ordinal
nature  of  the  classification:  CAS,  modified NOSPECS and EUGOGO classification.  The
scores of these scales are sums of the points measured based on the occurrence of various
symptoms. This means that, for example, for two orbits rated at three points on the NOSPECS
scale, the symptom set may differ. Because the nature of the scales does not allow for the
assumption  of  equal  distances  between  the  values,  an  analytical  method  free  from such
assumption  was selected  [7].  At  the  same time,  to  simplify the  presentation  of  statistical
description, the presented statistics were as for quantitative variables.  To check whether the
changes  in  the results  of  CAS,  the  modified NOSPECS classification,  and the EUGOGO
classification in TED patients following surgery were statistically reliable and whether the
score was related to the covariates included, hierarchical regression analysis was performed
for the ordinal data.
Results
The  most  common  indication  for  orbital  decompression  was  compressive  optic
neuropathy (61%, 31/51), followed by possible vision loss (31%, 16/51). Poor responders or
non-responders  to  GCs and  patients  with  intolerance  to  GCs were  determined  to  be  less
common, with a rate of 4% (2/51) of the cases. Cosmetic indication was noted in a similar
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number  of  patients  (4%,  2/51).  Treatments  used  before  surgery  were  as  follows:  topical
treatment, antithyroid drugs, oral or intravenous glucocorticoids, radioiodine, strumectomy,
orbital  radiotherapy,  and  alternative  management  (e.g.  immunoglobulins,  etc.).  Therapies
overlapped in most cases. 
An effective medical procedure was performed in one stage in 32 patients (57 orbits). In the
absence of improvement after the surgical treatment, 16 patients (24 orbits) underwent the
next  stage  of  treatment  (extension  of  the orbital  decompression range),  and 3 patients  (3
orbits) underwent the 3 stages of treatment. The overall rate of postoperative complications
was 15.47%. We observed sinonasal and orbital complications, where the most common was
facial hypoaesthesia of the trigeminal nerve branch innervation (5%).
The changes in the results of individual classifications are presented below:
CAS
Before surgery, the mean value of the CAS was 3.83 ± 1.86 points (values ranged between 0
and 7 points). After surgery, the CAS mean value was 2.07 ± 1.84 points (range 0–7 points)
regardless of the surgical approach used. At the descriptive level, after the surgical treatment,
lower average values of the CAS were recorded. Before surgery, 65 out of 84 orbits (77%)
were found to be in the active phase of the disease, and 28 orbits (33%) were found to be in
the active phase of the disease after surgery. The outcomes of the operation according to the
CAS classification indicated an improvement in 59 orbits  (70%), deterioration in 7 orbits
(9%), and no change in 18 orbits (21%).
The results with regard to surgical access used in the studied group of 51 patients were as
follows:
— before medial wall decompression (n = 52) — mean value 3.69 ± 1.86; after medial
wall decompression — mean value 1.87 ± 1.75; 
— before inferomedial wall decompression (n = 12) — mean value 3.92 ± 1.24; after
inferomedial wall decompression — mean value 1.92 ± 1.92;
— before mediolateral wall decompression (n = 20) — mean value 4.15 ± 2.18; after
mediolateral wall decompression — mean value 2.7 ± 1.87.
Table 1 shows a summary of the posterior distributions of the parameters for the full statistical
model.  It  was  noted  that  the  measurement  model  was  the  best  fit  to  the  data  and  the
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measurement effect coefficient was statistically reliable. This means that the results for CAS
have plausibly changed statistically but were not covariant dependent.
It was noted that the score obtained in the CAS classification was lower than that before the
operation. Before orbital decompression, the most common scores were values of 3, 4, and 5,
whereas after surgery, the most common values were 1, 2, and 3 (Fig. 1A).
GO severity according to the modified NOSPECS classification
The mean value of the  modified NOSPECS classification before orbital decompression was
3.31 ± 0.97 points (results ranged from 1 to 5 points). These measurements changed to 2.5 ±
0.97 points (results ranged from 0 to 4 points) after orbital decompression regardless of the
surgical approach used.
At the descriptive level, lower average modified NOSPECS classification scores after surgery
were obtained. The surgery resulted in better modified NOSPECS classification scores (lower
score) for 55 orbits (65%), worse scores (higher score) for 6 orbits (7%), and the same scores
for 23 orbits (27%).
The results with regard to surgical access used in the studied group of 51 patients (n = 84
orbits) were as follows:
— before medial wall decompression (n = 52) — mean value 3.23 ± 1.04; after medial
wall decompression — mean value 2.29 ± 1.00;
— before inferomedial wall decompression (n = 12) — mean value 3.75 ± 0.45; after
inferomedial wall decompression — mean value 2.92 ± 0.79;
— before mediolateral wall decompression (n = 20) — mean value 3.25 ± 0.97; after
mediolateral wall decompression — mean value 2.8 ± 0.83.
Table 2 shows a summary of the posterior distributions of the parameters for the full statistical
model.  It  was  noted  that  the  measurement  model  was  the  best  fit  for  the  data  and  the
measurement  effect  coefficient  was  statistically  reliable.  This  indicates  that  the  results
obtained in the modified NOSPECS classification changed statistically reliably but were not
dependent on the covariates.
The  modified NOSPECS classification results were lower after surgery. Before surgery, the
most  common  severity  scores  were  values  of  3  and  4,  whereas  after  surgery,  the  most
common values were 2 and 3 (Fig. 1B).
GO severity according to the EUGOGO classification
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Before surgery, mild GO occurred in 1 orbit (1%), moderate to severe GO in 21 orbits
(25%) and sight-threatening GO in 62 orbits (74%).
After  orbital  decompression,  lower  average  results  in  the  EUGOGO classification
were reported: mild GO was observed in 20 orbits (24%), moderate to severe GO in 48 orbits
(57%),  and  sight-threatening  GO  in  16  orbits  (19%).  The  surgery  outcomes  indicated
deterioration in 1 orbit (1%), improvement in 49 orbits (58%), and no change in 34 orbits
(40%). The results with regard to surgical access used in the studied group of 51 patients (n =
84 orbits) were as follows:
— before medial wall decompression (n = 52) — mild GO — 1 orbit (2%), moderate to
severe GO — 16 orbits (31%), and sight-threatening GO — 35 orbits (67%); after
medial wall decompression — mild GO — 13 orbits (25%), moderate to severe GO —
32 orbits (62%), and sight-threatening GO — 7 orbits (13%);
— before inferomedial wall decompression (n = 12) — mild and moderate to severe GO
— 0 orbits, and sight-threatening GO — 12 orbits (100%); after inferomedial wall
decompression — mild GO — 2 orbits (17%), moderate to severe GO — 7 orbits
(66%), and sight-threatening GO — 2 orbits (17%) 
• Before  mediolateral  wall  decompression  (n  =  20)  — mild  GO — 0  orbits  (2%),
moderate  to  severe GO — 5 orbits  (25%),  and sight-threatening GO — 16 orbits
(75%);  after  mediolateral  wall  decompression  —  mild  GO  —  5  orbits  (25%),
moderate to severe GO — 9 orbits (45%), and sight-threatening GO — 7 orbits (35%).
Table 3 shows a summary of the posterior distributions of the parameters for the full
statistical model. It should be noted that the measurement model was the best fit for the data
and the measurement effect coefficient was statistically reliable. This means that the results of
the  EUGOGO  classification  changed  statistically  credibly  but  were  not  dependent  on
covariates. As expected, the EUGOGO scores were lower after surgery. Before surgery the
most  common  point  score  was  2  (vision-threatening  form),  whereas  after  surgery  the
dominant value was 1 (moderate to severe form) (Fig. 1C). Table 4 shows the summary of the
results in the endocrinological classifications before and after orbital decompression.
The  statistical  analysis  of  the  examined  ophthalmic  parameters  in  relation  to  covariates
showed the following:
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— the results for the CAS,  modified NOSPECS, and EUGOGO classification changed
statistically reliably but were not  covariant dependent.  All  scores were lower after
orbital decompression;
— the results  of endocrinological  parameters  did not change in  a  statistically reliable
manner depending on the type of decompression applied;
— no statistically reliable changes were observed in the results of the endocrinological
parameters in correlation with the type of previously used non-surgical treatment of
thyroid orbitopathy.
— better  results  in  terms  of  applied  classifications  were  observed  in  the  active
phase/more severe stage of the disease.
Discussion
Only a few studies available in the literature (2010–2020) investigated the outcomes of
TED  treatment  with  orbital  decompression  based  on  the  endocrinological
scores/classifications.  Many classifications  are  used  to  assess  the  activity  and severity  of
thyroid orbitopathy.  These scales are used more often by endocrinologists  than by orbital
surgeons, and their results are discussed in studies on treatment. Research into the surgical
treatment  of  TED  usually  excludes  the  changes  assessed  using  endocrine  classifications.
There  are  a  few modifications  in  the  NOSPECS  classification,  in  which  the  ophthalmic
parameters used for its assessment are altered, the number of assessed parameters is reduced,
or the scoring method is different [22–25]
Jefferis  et  al.  discussed the results  of the treatment of 55 patients (93 orbits)  who
underwent  orbital  decompression.  In  their  studies,  they  presented  data  on  the  mean
preoperative CAS, which was 1.4 ± 2.0 points before surgery.  In  the active phase of  the
disease the patients scored an average of 3.9 ± 2.5 points, whereas in the inactive phase they
reportedly scored 0.9 ± 1.4 points. The authors did not evaluate the patients after surgical
intervention [26]. 
Lal et al. presented the results of endoscopic medial wall decompression in 12 patients
(24 orbits). In the preoperative assessment, they used the NOSPECS classification and a 10-
point CAS classification. Based on the NOSPECS classification, 7 patients (58%) qualified
for stage III of GO, 2 patients (17%) for stage IV, 1 patient (8%) for grade V, and 2 patients
(17%) for up to grade VI classification. Meanwhile, as per the CAS classification, 11 patients
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(92%) were in the inactive phase of the disease, whereas 1 patient (8%) was in the active
phase of the disease. Moreover, Lal et al. analysed the results of endoscopic decompression of
the medial wall of the orbit in 12 patients (24 orbits). The authors did not assess the study
group using these classifications after performing surgery [27]. 
Oh  et  al.  also  analysed  the  results  of  treatment  after  maximal  lateral  wall
decompression  with  adipose  tissue  removal  in  24  patients  (31  orbits).  They assessed  the
patients before and after surgery using the CAS classification. Before orbital decompression,
the mean CAS for the operated orbits was 9.5 ± 0.4 points. Six months after the surgical
treatment, this index was 2.9 ± 0.4 points, and after a year it was 2.1 ± 0.6 points (p < 0.01).
For non-operated contralateral orbits, the result was 7.4 ± 0.3 points before the surgery, 3.5 ±
0.1 points after the first 6 months, and 3.2 ± 0.5 points 1 year after the surgery (p < 0.05) [28].
Miśkiewicz et al. reported the results of the treatment of 10 patients (18 orbits) with
dysthyroid neuropathy treated with endoscopic medial wall decompression and high doses of
GCs. They assessed the patients using the CAS classification. Before surgery, they recorded a
CAS mean value of 4 (range 2–6 points) and a CAS point reduction from 4 to 2 points (range
0–3 points) after treatment [29].
In our group of TED patients treated with orbital decompression, the results of the 7-
point CAS classification showed that before the surgery, 76% of the orbits were in the active
phase of the disease (> 3 points), whereas 24% were determined to be in the inactive phase (≤
3 points). Before surgery, the mean value of CAS was 3.83 ± 1.86 points (range 0–7 points),
and after surgery, the mean value was 2.07 ± 1.84 points (range 0–7 points) regardless of the
surgical  technique  used.  In  the  pre-  and  postoperative  CAS analysis,  better  results  were
observed in patients with the active phase of the disease. This observational study is valuable
because most articles address the surgical treatment in the inactive phase of disease. However,
one limitation of this observational study is the smaller group of inactive TED patients (19
inactive vs. 65 active orbits). Similarly, based on the NOSPECS classification, those patients
that worsened had lower results preoperatively, but the group was small. The most common
values in the NOSPECS classification before surgery were 3 and 4, whereas after surgery, the
most common values were 2 and 3. The weak point of this paper was that we only had the
possibility to classify the patients in NOSPECS as class 0–6 without determining the degree
of severity in each class. In the EUGOGO classification, the best results were observed in a
group of patients with sight-threatening disease, whereas no changes were observed in the
moderate to severe (20) and mild (1) patients. 
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The Bayesian statistical analysis showed that postoperative changes in the CAS classification,
modified NOSPECS classification and the transition from a higher  to a lower severity of
EUGOGO classification were statistically reliable. 
When analysing those results, it should be emphasised that this paper, in contrast to
other papers, presents a majority of patients operated in the active form of the disease (76%).
The  endocrinological  classifications  have  been  determined  to  be  very  helpful  in  the  GO
patients’ assessment, but they should be utilised consciously. Surgical decompression does not
change the patients’ endocrine status, and even though the patients reach the inactive phase
after orbital decompression according to CAS, they should be carefully followed by a group
of specialists in this field. Those results lead to the question of whether we should change the
scoring system of activity of the disease or whether these scoring systems should indicate that
the patient was assessed after surgery. 
Thirteen  patients  underwent  a  postoperative  examination  less  than  one  month  after  the
surgical intervention, and the rest more than one month after the surgical intervention. The
initial  comparison  of  the  groups  shows  better  results  (lower  scores  obtained  in  the
classifications) in patients with a follow-up examination longer than a month.  Due to the
small size of the groups, it is difficult to analyse them statistically. This observation may be
explained by the fact that postoperative healing usually takes 3–4 weeks. More research is
needed to assess the impact of time since surgery on the results of endocrine classifications.
Conclusions
Based on the analysis of the results obtained, it can be concluded that orbital decompression is
an effective treatment method in patients with TED. Even though the surgical decompression
in TED may become less relevant due to the development in pharmacotherapy - especially in
biological  treatment,  it  can  still  be  considered  as  the  tool  for  non-responders  to
pharmacological  decompression.  Orbital  decompression  results  in  an  improvement  in
endocrinological assessment with commonly used classifications. 
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Table 1.  The results of the hierarchical ordinal regression analysis  with the results of the
Clinical Activity Score classification as a dependent variable
DV: CAS   95% CI
Parameter M SE LI UI
β
Constant [1] −1.85 0.51 −2.87 −0.91
Constant [2] −0.81 0.46 −1.76 0.07
Constant [3] −0.31 0.43 −1.2 0.56
Constant [4] 0.73 0.45 −0.16 1.6
Constant [5] 0.99 0.48 0.03 1.95
Constant [6] 2.45 0.55 1.41 3.62
Constant [7] 2.8 0.75 1.42 4.29
Measurement −0.82 0.12 −1.07 −0.6
Orbit 0.04 0.09 −0.13 0.21
Decompression [1]* −0.15 0.2 −0.55 0.25
Decompression [2]* −0.09 0.32 −0.7 0.52
Antithyroid drugs 0.01 0.22 −0.41 0.45
Radioiodine 0.35 0.24 −0.11 0.85
Strumectomy 0.14 0.27 −0.34 0.71
Orbital radiotherapy −0.3 0.28 −0.9 0.23
TRAb concentration 0.03 0.02 0 0.07
GCs IV (total dose) 0.12 0.08 −0.03 0.27
Τ Constant 1.38 0.26 0.92 1.95
Comparison of models ΔLOOIC SE
Measurement null −92.95 14.09
Full measurement 5.95 4.95   
Constants 1–7 are the estimated distances between the CAS levels on a latent score; DV —dependent
variable; CI — credibility interval; M — median; SE — standard error; LI/UI — lower/upper interval;
β — regression coefficients; τ — standard deviation of individual constant values (β); * — nominal
variables 
Table 2.  The results of the hierarchical ordinal regression analysis  with the results  of the
modified NOSPECS classification as the dependent variable
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DV:  modified  NOSPECS
classification   
95% CI
Parameter M SE LI UI
β
Constant [1] −8.76 1.66 −12.2 −5.82
Constant [2] −5.41 1.04 −7.59 −3.45
Constant [3] −0.68 0.78 −2.27 0.92
Constant [4] 2.16 0.82 0.68 3.83
Constant [5] 7.26 1.19 5.17 9.72
Measurement −1.56 0.24 −2.04 −1.13
Orbit* 0.08 0.17 −0.27 0.42
Decompression [1]* −0.31 0.48 −1.27 0.62
Decompression [2]* 0.51 0.68 −0.83 1.85
Antithyroid drugs 0.03 0.49 −0.95 0.98
Radioiodine 0.21 0.55 −0.88 1.31
Strumectomy 0.53 0.59 −0.61 1.68
Orbital radiotherapy 0.26 0.64 −0.96 1.54
TRAb 0.06 0.04 −0.02 0.15
GCs IV – total dose −0.15 0.17 −0.49 0.19
Τ Constant 3.18 0.56 2.18 4.42
Comparison of models ΔLOOIC SE
Measurement null −82.74 16.19
Full measurement 6.01 3.24   
Constants 1–5 are the estimated distances between modified NOSPECS levels on a latent scale; DV —
dependent variable; CI — credibility interval; M — median; SE — standard error; LI/UI — lower
/upper interval; β — regression coefficients; τ — standard deviation of individual constant values (β);
* — nominal variables 
Table 3.  The results of the hierarchical ordinal regression analysis  with the results of the
EUGOGO classification as the dependent variable
DV: EUGOGO classification   95% CI
Parameter M SE LI UI
Constant [1] −5.26 1.21 −7.98 −3.28
16
β
Constant [2] 0.3 0.82 −1.31 1.92
Measurement −2.73 0.52 −3.85 −1.86
Orbit* −0.02 0.24 −0.49 0.43
Decompression [1]* −0.37 0.54 −1.42 0.7
Decompression [2]* 0.21 0.82 −1.34 1.9
Antithyroid drugs 0.41 0.57 −0.67 1.64
Radioiodine −0.37 0.6 −1.59 0.76
Strumectomy 1.17 0.68 −0.05 2.69
Orbital radiotherapy −0.82 0.72 −2.35 0.61
TRAb 0.08 0.05 −0.01 0.18
GCs IV – total dose −0.08 0.18 −0.45 0.27
Τ Constant 3.28 0.81 1.95 5.08
Comparison of models ΔLOOIC SE
Measurement null −101.05 14.98
Full measurement 6.82 5.54   
Constants  [1–2]  are  the  estimated  distances  between  EUGOGO levels  on  a  latent  scale;  DV —
dependent  variable;  CI  —  credibility  interval;  M  —  median;  SE  —  standard  error;  LI/UI  —
lower/upper  interval;  β  — regression  coefficients;  τ  — standard  deviation  of  individual  constant
values (β); * — nominal variables
Table 4. Endocrine classification results before and after orbital decompression (n = 84).






















Clinical activity score (type)
Active 65 76 28 33 59 91 6 7 0 0
Non-active 19 24 56 67 0 0 12 63 7 37
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GO severity according to the modified NOSPECS classification (points) 
0 0 0 2 2 0 0 0 0 0 0
1 4 5 7 8 1 25 0 0 3 75
2 13 15 39 46 6 46 5 38 2 16
3 28 33 22 26 20 71 7 25 1 4
4 33 40 14 17 22 65 11 35 0 0
5 6 7 0 0 6 100 0 0 0 0
6 0 0 0 0 0 0 0 0 0 0
GO severity according to the EUGOGO classification (type)
Mild 1 1 5 6 0 0 1 100 0 0
Moderate to severe 20 25 61 73 4 20 15 75 1 5
Sight-threatening 63 74 18 21 45 71 18 29 0 0
Figure  1A-C.  Results  of  the  CAS  (A),  modified  NOSPECS  (B),  and  EUGOGO  (C)
classification  before  and  after  orbital  decompression.  Box  plots  show  the  distribution  of
individual values. Points connected by purple lines are pairs of observations for the same
orbit. The black points show the estimated marginal probabilities for a given value of each
score (CAS, NOSPECS, EUGOGO) at a given time of measurement. The horizontal black
lines are the 95% credibility intervals for the probability estimation
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